MobiDig: Mobile and Digital Application in Heart Failure Networks Berlin/Brandenburg

Sponsor
German Heart Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05422859
Collaborator
Federal Ministry of Health, Germany (Other)
50
3
1
6
16.7
2.8

Study Details

Study Description

Brief Summary

The MobiDig trial is designed to evaluate an implementation of a mobile phone application with secondary preventive/rehabilitative modules for patients with heart failure in certified Heart Failure Unit centers in Berlin and Brandenburg.

The aim is to evaluate the effect on quality of life, symptoms and the course of the disease. In addition, the acceptance, adherence and user behavior as well as the implementation potential for a permanent introduction of the application in national heart failure networks will be analyzed.

Condition or Disease Intervention/Treatment Phase
  • Other: MobiDig
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Mobile and Digital Application in Heart Failure Networks Berlin/Brandenburg
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: MobiDig

50 patients will have access to a mobile phone application for 3 months.

Other: MobiDig
The application will contain the following modules: information and knowledge about heart failure; vital sign diary, which can be sent to the certified HFU pedometer (individualized step-goal), cardiac home training videos "frequently asked questions" and connection to a certified HFU provider by a heart failure hotline

Outcome Measures

Primary Outcome Measures

  1. Acceptance of the application [3 months]

    The acceptence of the application will be measured by the User Experience Questionnaire. It consists of 9 items that can be rated on a 7-point Likert scale. -3 (fully agree with negative term) to +3 (fully agree with positive term). A higher total score means a better outcome.

  2. Change in quality of life [Baseline and 3 months]

    Quality of life measured by Kansas City Cardiomyopathy Questionnaire using the validated 12-item version which has been described by Spertus et Jones (doi: 10.1161/CIRCOUTCOMES.115.001958.) A higher score means a better outcome.

  3. Patient reported outcomes [Baseline and 3 months]

    Health-related quality of life will be measured by the "Patient Related Outcome and Measurement Information System" (PROMIS) test. Including 23 items that will be analyzed via Likert scale 1 (impossible/never) to 5 (no limitations/very good). A higher score means a better outcome.

  4. Change in symptoms of heart failure [Baseline and 3 months]

    Symptoms of heart failure will be assessed by the New York Heart Association functional class. Consisting of four classes (I-IV), the higher, the worse the outcome.

  5. Change in six-minute walk distance [Baseline and 3 months]

    Functional capacity will be assessed by the 6-minute walk test

  6. Change in daily walking distances [Baseline and 3 months]

    Functional capacity will be assessed by the steps taken within 24 hours (pedometry).

  7. Change in heart failure biomarker [Baseline and 3 months]

    Heart failure severity will be assessed by the biomarker NT-proBNP.

  8. Number of hospitalizations [3 months]

    Number of hospitalizations for heart failure will be assessed.

  9. Length of hospitalizations [3 months]

    Length of in-hospital stay of hospitalizations for heart failure will be assessed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Confirmed diagnosis of heart failure

  • Treatment in a certified Heart Failure Unit center in Berlin or Brandenburg

  • Written informed consent of the participants

  • User of a mobile device with an iOS operating system

Exclusion Criteria:
  • Addiction or other illnesses that do not allow the participants to assess the nature and scope as well as possible consequences of participation or its scientific evaluation

  • insufficient knowledge of the German language, which is necessary to use the application

Contacts and Locations

Locations

Site City State Country Postal Code
1 Isabell A Just Berlin Deutschland Germany 13353
2 Charité - Universitätsmedizin Berlin: Campus Virchow-Klinikum Berlin Germany 13353
3 Herzzentrum Berlin Bernau Germany

Sponsors and Collaborators

  • German Heart Institute
  • Federal Ministry of Health, Germany

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sabine Huebler, Head of Studienzentrale, German Heart Institute
ClinicalTrials.gov Identifier:
NCT05422859
Other Study ID Numbers:
  • MobiDig
First Posted:
Jun 21, 2022
Last Update Posted:
Jun 21, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2022